➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Johnson and Johnson
Medtronic
Harvard Business School
Dow

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Collagenase - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for collagenase

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Endo PharmceuticalsPhase 3
Foundation for Orthopaedic Research and EducationPhase 3
Rejuven Dermaceutical Co., Ltd.Phase 1

See all collagenase clinical trials

Recent Litigation for collagenase

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
KYTHERA BIOPHARMACEUTICALS, INC. v. SLAYBACK PHARMA LLC2018-11-08
Tissue Regeneration Technologies, LLC v. Male Performance Medical Partnership, LLC2018-10-04

See all collagenase litigation

PTAB Litigation
PetitionerDate
2020-01-28
2018-07-17
2017-04-04

See all collagenase litigation

Pharmacology for collagenase
Ingredient-typeCollagenases
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for collagenase Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for collagenase Derived from Company Disclosures

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Auxilium Pharms XIAFLEX collagenase clostridium histolyticum SOLUTION; INJECTION 125338 001 2010-02-02 ⤷  Free Forever Trial Advance Biofactures of Curacao (Curacao, AN) 2039-03-29 RX Orphan company
Auxilium Pharms XIAFLEX collagenase clostridium histolyticum SOLUTION; INJECTION 125338 001 2010-02-02 ⤷  Free Forever Trial Auxilium US Holdings, LLC (Wilmington, DE) 2026-01-30 RX Orphan company
Auxilium Pharms XIAFLEX collagenase clostridium histolyticum SOLUTION; INJECTION 125338 001 2010-02-02 ⤷  Free Forever Trial Advance Biofactures Corporation (Lynbrook, NY) 2039-02-26 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

3) Low Certainty: US Patents for collagenase Derived from Patent Text Search

These patents were identified by searching patent claims

Supplementary Protection Certificates for collagenase

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90041-0 Sweden ⤷  Free Forever Trial MARKNADSGODKAENNANDE NR.: EU/1/13/819/001, 2013-03-15, MIKROPLASMIN
2013000076 Germany ⤷  Free Forever Trial PRODUCT NAME: MIKROPLASMIN; REGISTRATION NO/DATE: EU/1/13/819/001 20130313
2018000065 Germany ⤷  Free Forever Trial PRODUCT NAME: DEOXYCHOLSAEURE NATRIUMSALZ; NAT. REGISTRATION NO/DATE: 98586.00.00 20180104; FIRST REGISTRATION: IS IS/1/16/071/01 20160729
0452 Netherlands ⤷  Free Forever Trial PRODUCT NAME: AGALSIDASE ALFA; REGISTRATION NO/DATE: EU/1/01/189/001 20010807
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Express Scripts
Johnson and Johnson
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.